-
The development of the medical industry has entered a period of transformation, and major companies have set off a financing boom
Time of Update: 2021-10-01
On September 16, Gaorong Technology, a minimally invasive interventional surgery robot company for tumors, announced that it has completed a Pre-A round of financing of tens of millions of yuan.
-
The first topical JAK inhibitor approved by the FDA for the treatment of atopic dermatitis
Time of Update: 2021-10-01
Incyte today announced that the US FDA has approved Opzelura (ruxolitinib) cream for short-term and non-continuous long-term treatment of patients with mild to moderate atopic dermatitis (AD) over 12 years old .
-
With one shot, the cancer cells disappear!
Time of Update: 2021-10-01
According to the industry, although CAR-T drugs are expensive, such as a single dose of Akirensai injection reaching 1.
In addition, it’s worth noting that WuXi Junuo issued an announcement on September 3 that its CAR-T product targeting CD19, Ruiji Oransay injection, was approved for marketing .
-
A large number of commonly used proprietary Chinese medicines are expected to usher in a big price cut!
Time of Update: 2021-10-01
The industry believes that a batch of proprietary Chinese medicine companies will be eliminated in the future, especially small-scale and non-specialized small companies that may gradually fade out of the hospital market and move to the OTC and e-commerce markets; and have a Chinese medicinal planting base to obtain Large enterprises with advantages such as GAP certification, intelligent manufacturing, and professional promotion are expected to break through the centralized procurement competition and obtain opportunities for high-quality and rapid development .
-
What is the explanation for the “professional mismatch” status of licensed pharmacists in DTP pharmacies?
Time of Update: 2021-10-01
The lack of professional abilities of licensed pharmacists and patients' lack of understanding of the role of pharmacy services have led to the current DTP investors' belief that licensed pharmacists are only GSP requirements, and they even regard licensed pharmacists as "senior cold chain distributors.
-
The results of the selection of artificial joints in the country were announced: 44 companies were selected, with an average drop of over 80%
Time of Update: 2021-10-01
On the evening of September 14, the results of the artificial joint national procurement, which has attracted much attention from the industry, were announced: 44 of the 48 companies that participated in the centralized procurement quotation this time were selected, with a winning rate of 92% .
-
Changsha draws a new blueprint for the development of the biopharmaceutical industry, achieving 250 billion revenue by 2025
Time of Update: 2021-10-01
Recently, according to the "14th Five-Year Plan" of Changsha's biomedical industry, by 2025, the total output value (revenue) of Changsha's biomedicine (including gene technology) industry will reach 250 billion yuan, and there will be about 30 listed companies .
-
Viterilon's first new drug, SIR1-365 tablets, was approved for clinical use in China
Time of Update: 2021-10-01
According to Viterilon’s official website, in animal experiments, inhibiting RIP1 kinase through small molecule drugs or gene editing can effectively prevent or reduce the development of a series of diseases, including multiple sclerosis (EAE model), Alzheimer’s disease, amyotrophic lateral sclerosis, systemic inflammatory response syndrome .
-
Two pharmaceutical companies join forces to promote the commercialization of innovative domestic diabetes drugs
Time of Update: 2021-10-01
The two parties will carry out in-depth cooperation in logistics and warehousing, supply chain management and channel informatization, and jointly promote Hua Medicine’s first-in-class new drugs.
-
The medical-grade wearable device market, which has been flooded by a large number of companies, still needs time to break out
Time of Update: 2021-10-01
For example, in 2015, "Made in China 2025" was officially released, which emphasized the need to improve the innovation capability and industrialization level of medical devices, and promote mobile Internet, cloud computing, big data and other technologies in smart Breakthrough in the manufacturing field, focusing on the development of mobile medical products such as wearables and remote diagnosis and treatment.
-
my country's pharmaceutical manufacturing industry is ushering in a "golden development period", and the pharmaceutical machinery industry will also benefit
Time of Update: 2021-10-01
It should be noted that despite policy support, increased investment, and the continued improvement of the pharmaceutical environment, the pharmaceutical equipment industry will usher in opportunities .
-
Dongfang Huakang Chinese Medicine Yiqi Tongqiao Pills Approved for Listing
Time of Update: 2021-10-01
is the holder of the marketing license for the drug .
This product is a new traditional Chinese medicine compound preparation developed on the basis of clinical experience.
-
BMS submitted LAG-3+PD-1 fixed-dose compound market application and received FDA priority review
Time of Update: 2021-09-30
The results showed that the fixed-dose combination of relatlimab and nivolumab as a first-line therapy for previously untreated patients with metastatic or unresectable melanoma achieved statistically and clinically significant progression-free survival (PFS) benefits compared to Opdivo monotherapy (10.
-
FDA approves first in class ADC drug to treat cervical cancer
Time of Update: 2021-09-30
Article source: Medical Rubik's Cube InfoOn September 20, Genmab/Seagen announced that the FDA has accelerated the approval of Tivdak (tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer during or after chemotherapy .
-
Lion Biotech announces that the FDA has approved the IND clinical application of its leading product LioCyx-M004 for the treatment of hepatocellular carcinoma
Time of Update: 2021-09-30
This new drug approval allows Lion Biotech to start an IND clinical trial of its leading product LioCyx-M004 for the treatment of primary HBV-related advanced hepatocellular carcinoma (HCC) .
-
Institutional enthusiasm and 37 listed pharmaceutical companies get together for investigation
Time of Update: 2021-09-30
In the interactive session, the organization paid close attention to issues such as the future development plan of Jianfan Biology in the international market, the future layout of the company's nephrology products in the hospital, and how to deal with the risks of centralized procurement.
-
PD-1's "involution" intensifies, and it will fight for these two capabilities in the future
Time of Update: 2021-09-30
According to a Southwest Securities research report, as of February 2021, there are 154 PD-1 monoclonal antibodies under development worldwide, of which 8 have been listed, 5 are in the application for listing stage, and 7 are in the phase III clinical stage .
-
Following PD-1, CAR-T, and ADC, another drug has become a new trend!
Time of Update: 2021-09-30
With more and more companies in the field of anti-double-antibodies, the phenomenon of R&D may appear in the future, the track will also become crowded, and the homogenization competition will become more intense.
-
Chinese herbal medicines set off a wave of price increases, and the industry suggests multiple measures to break through
Time of Update: 2021-09-30
The prices of 60% of Chinese medicinal materials have risen to varying degrees, and some medicinal materials have even increased by more than 100% .
At present, a large number of Chinese medicine companies have been affected in the context of the continuous price increase of Chinese medicinal materials .
-
AZ/Daiichi Sankyo Enhertu Head-to-Head Phase 3 Clinical: Curative Effect Beats Roche Kadcyla
Time of Update: 2021-09-30
The data shows: Among patients with HER2-positive unresectable and/or metastatic breast cancer who have received trastuzumab and taxane, the HER2-targeted antibody conjugate (ADC) Enhertu (trastuzumab deruxtecan) has significantly better efficacy Roche's HER2 targeted ADC product Kadcyla (trastuzumab emtansine, T-DM1) has observed high and consistent significant benefits in multiple efficacy endpoints and key subgroups .
